ChemBriefNovartis strikes about $7.8 billion mRNA deal with China's Abogen
Novartis has entered into a $7.8 billion licensing and option agreement with Chinese biotech firm Abogen to advance RNA-based therapies.
reuters · 2026-10-02 00:31
1 articles
Novartis has entered into a $7.8 billion licensing and option agreement with Chinese biotech firm Abogen to advance RNA-based therapies.